Suven Life Sciences informs about press release

24 Sep 2019 Evaluate

Suven Life Sciences has informed that it has enclosed Press Release of the company titled First Patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA.

The above information is a part of company’s filings submitted to BSE.

Suven Life Sciences Share Price

170.95 2.50 (1.48%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×